All In Biotech

Drug Trial Radar · NCT04884035

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Sep 15, 2021

Primary completion

Dec 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

Conditions

  • Lymphoma, B-Cell

Interventions

  • CC-220Drug

    CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

  • RituximabDrug

    Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles

  • CyclophosphamideDrug

    Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles

  • DoxorubicinDrug

    Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

  • VincristineDrug

    Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

  • PrednisoneDrug

    Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles

  • CC-99282Drug

    CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

  • Polatuzumab vedotinDrug

    Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

  • RituximabDrug

    Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) - Part 1Time frame: During the first 2 cycles of treatment (each cycle is 21 days)
  2. Recommended Phase 2 Dose (RP2D) - Part 1Time frame: During the first cycle of treatment (each cycle is 21 days)
  3. Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2Time frame: From the first dose of any IP until 28 days after the last dose of IP
  4. Maximum Tolerated Dose (MTD) - Part 2ATime frame: During the first cycle of treatment (each cycle is 21 days)
  5. Recommended Phase 2 Dose (RP2D) - Part 2ATime frame: During the first cycle of treatment (each cycle is 21 days)

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • Local Institution - 162

    Birmingham, Alabama

  • Local Institution - 154

    Scottsdale, Arizona

  • Local Institution - 169

    Duarte, California

  • Local Institution - 160

    Jacksonville, Florida

  • Local Institution - 161

    Marietta, Georgia

  • Local Institution - 159

    Kansas City, Kansas

  • Local Institution - 166

    Wichita, Kansas

  • Local Institution - 152

    Rochester, Minnesota

  • Local Institution - 163

    Saint Louis Park, Minnesota

  • Local Institution - 151

    Omaha, Nebraska

  • Local Institution - 170

    Charlotte, North Carolina

  • Local Institution - 164

    Winston-Salem, North Carolina

  • Local Institution - 155

    Houston, Texas

  • Local Institution - 168

    Murray, Utah

  • Local Institution - 171

    St. George, Utah

  • Local Institution - 503

    Perth, Australia

  • Local Institution - 501

    Adelaide, South Australia, Australia

  • Local Institution - 702

    Athens, Greece

  • Local Institution - 704

    Athens, Greece

  • Local Institution - 701

    Athens, Greece

  • Local Institution - 700

    Thessaloniki, Greece

  • Local Institution - 601

    Gdansk, Poland

  • Local Institution - 600

    Krakow, Poland

  • Local Institution - 603

    Słomniki, Poland

  • Local Institution - 602

    Warsaw, Poland

  • Local Institution - 604

    Wroclaw, Poland

  • Local Institution - 605

    Skórzewo, Greater Poland Voivodeship, Poland

  • Local Institution - 300

    Seoul, South Korea

  • Local Institution - 302

    Seoul, South Korea

  • Local Institution - 301

    Seoul, South Korea

  • Local Institution - 201

    Barcelona, Spain

  • Local Institution - 203

    Málaga, Spain

  • Local Institution - 200

    Salamanca, Spain

  • Local Institution - 403

    Taichung, Taiwan

  • Local Institution - 402

    Taichung, Taiwan

  • Local Institution - 400

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.